Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 399

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 399
---
 and commercialize MultiplAI’s tests in Latin America. This agreement would minimize risks for both entities while leveraging our respective core strengths. It also would facilitate data sharing and acquisition, allowing us to integrate MultiplAI’s products within our Heritas precision medicine business unit. On August 11, 2024, MultiplAI, the Company, and Parent entered into a term sheet for the Reseller License Agreement, pursuant to which MultiplAI granted OmnigenicsAI an exclusive license to market certain products in Latin America through December 31, 2030. Concurrently with the Restructuring, the Parent has agreed to contribute to OmnigenicsAI receivables totaling $395,260 owed by MultiplAI to Parent pursuant to loan agreements entered 200 into by the Parent and MultiplAI in the period between the signing of the Business Combination Agreement and the termination of the MultiplAI Share Purchase Agreement. This binding term sheet was entered into in the context of negotiations relating to the termination of the MultiplAI Share Purchase Agreement. Strategic Focus Post-Termination The termination of the SPA with MultiplAI allow us to refocus our strategic efforts on expanding our market presence in Latin America — a region with considerable growth potential. This focus ensures that we can develop and mature our products and services in an underserved market, establishing a robust entry barrier against international competitors. By concentrating capital expenditures and operational expenditures on regional growth, we aim to maximize value creation for our shareholders. AI Integration and Future Development MultiplAI’s AI technology primarily utilizes classic machine learning algorithms. However, we have adopted a broader and more ambitious strategy, focusing on the development of Generative AI foundation models. These models will be trained by omni -modaldata collected from our comprehensive services suite. The data obtained through the commercial agreement which we expect to enter into with MultiplAI will further enhance these foundation models. To support our AI strategy, we plan to build our in -houseexpertise to develop AI and genomic solutions. This self -developmentapproach involves bringing together a specialized team of AI and genomics experts, utilizing more advanced and user -friendlytechnology to enhance the accuracy, precision, and overall performance of its genomic services while significantly reducing costs. Our strategic vision includes the creation of AI Agents, aimed at generating additional revenue streams and providing value to pharmaceutical companies, medical institutions, and clinical labs. We plan to derive these AI Agents from pre -trainedfoundation models, designed to support diverse health management scenarios. Despite the Notice of Termination and Multipl